Rule 1: Molecules with the substructure "CC(=O)N=C(N)N" or "CC(=O)ON=C(N)N" are likely have side-effect activity related to neoplasms benign, malignant and unspecified (incl cysts and polyps).
Rule 2: Molecules with the substructure "C#N" are unlikely to have side-effect activity related to hese neoplasms.
Rule 3: Molecules with the substructure "Cc1ccc(cc1)Oc2ccccc2" are likely have side-effect activity related to these neoplasms.
Rule 4: The presence of functional groups like carbonyls or amines in a compound may increase its potential for causing adverse effects.
Rule 5: A compound containing multiple or fused rings may have higher potential for causing adverse effects due to its increased stability and lipophilicity.
Rule 6: Compounds with high molecular weight or complex structures may be more likely to cause adverse effects due to decreased solubility and bioavailability.
Rule 7: Molecules with the substructure "CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3" are likely to have side-effects related to these neoplasms.
Rule 8: Molecules with the substructure "C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl" are unlikely to have side-effect activity related to these neoplasms.
Rule 9: Compounds containing benzene ring or heterocyclic aromatic system are potentially carcinogenic.
Rule 10: Molecules with nitro groups may have potential mutagenic and carcinogenic effects. 
Rule 11: Molecules containing sulfhydryl groups may have potential toxic effects on the body.
Rule 12: If a molecule contains a carbonyl group (C=O), it may have potential adverse effects related to these neoplasms.
Rule 13: Compounds with strontium ion (Sr+2) or calcium ion (Ca+2), have potential to cause adverse effects related to these neoplasms.
Rule 14: Compounds with a fluorine atom bonded to a carbon atom have potential to cause adverse effects related to these neoplasms.
Rule 15: Compounds with a sulfonyl group (SO2R) have potential to cause adverse effects related to these neoplasms. 
Rule 16: Compounds containing a sulfonamide group (-SO2NH-) or other similar functional group have the potential to cause adverse effect related to these neoplasms.
Rule 17: Compounds with nitro group (-NO2) or similar functional group may cause adverse effects related to these neoplasms.
Rule 18: Compounds with benzene ring or similar aromatic system may cause adverse effects related to these neoplasms.
Rule 19: Compounds containing substructure "CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O" or "C(CC(=O)O)CO" could have potential adverse effects related to these neoplasms.
Rule 20: Molecules containing a sulfonamide group (-SO2NH-) or similar functional group may have potential adverse effects related to these neoplasms.
Rule 21: Compounds with nitro group (-NO2) attached to an aromatic ring may have potential adverse effects related to these neoplasms.
Rule 22: Compounds with halogen atoms such as chlorine (Cl) or fluorine (F) may have potential adverse effects related to these neoplasms.
Rule 23: Presence of sulfonamide group in a compound may lead to side effects such as skin irritation or allergic reactions.
Rule 24: Presence of halogen atoms like chlorine or bromine in a compound can cause reproductive toxicity.
Rule 25: Certain chemical bonds such as double or triple bonds can increase the likelihood of toxic side effects.
Rule 26: Molecules containing a benzene ring (represented by the SMILES string C6H5) or a naphthalene ring (represented by the SMILES string C10H7) are likely to have adverse effects related to these neoplasms.
Rule 27: Presence of guanidine group (-C(NH2)=NR) or a urea group (-CONH-) might cause adverse effects related to these neoplasms.
Rule 28: Molecules that contain a nitro group (-NO2) are likely to have adverse effects related to these neoplasms.
Rule 29: Presence of sulfonyl group (-SO2R) might affect causing adverse effects related to these neoplasms.
Rule 30: Molecules containing a halogen atom such as chlorine or fluorine attached to a carbon atom are likely to have adverse effects related to these neoplasms. 
Rule 31: Presence of certain functional groups in a molecule such as a carbonyl group (C=O) or a sulfhydryl group (SH) might increase its reactivity and make it more likely to interact with biological molecules to cause harm.
Rule 32: Size and shape of a molecule can also affect its ability to interact with other molecules and cause adverse effects.
Rule 33: Chemical composition of a molecule can also play a role in determining its toxicity. Certain elements such as metals and halogens may increase its reactivity.
Rule 34: Compounds containing a nitro group (-NO2) may have potential adverse effects related to these neoplasms.
Rule 35: If a molecule contains a sulfonyl group (-SO2R), it may have potential adverse effects related to these neoplasms.
Rule 36: If a molecule contains a halogen atom such as chlorine or fluorine, it may have potential adverse effects related to these neoplasms.
Rule 37: Compounds containing a fluorine atom in its structure may increase the risk of developing adverse effects including cancer.
Rule 38: Compounds that contain sulfur or phosphorus atoms may have the potential to cause adverse effects including cancer due to their ability to form reactive metabolites that can damage DNA and other cellular components.
Rule 1: Molecules containing sulfonamide group (-SO2NH-) or nitro group (-NO2) may cause adverse effects related to neoplasms benign, malignant, and unspecified.
Rule 2: A molecule carrying fluorine atom bonded to a carbon atom and a carbonyl group (-C=O) between two aromatic rings may cause adverse effects related to neoplasms.
Rule 3: The existence of a nitrogen-containing ring system like pyridine or pyrimidine with at least one chlorine atom attached to any carbon atom within the ring system may trigger adverse effects related to neoplasms.
Rule 4: If sulfonyl group (SO2R) or carbonyl group (COR) is present in a molecule, it may lead to adverse effects related to neoplasms.
Rule 5: Presence of a cyano group (-CN) in a molecule may cause adverse effects related to neoplasm.
Rule 6: A molecule with a sulfhydryl group (-SH) or a disulfide bond (-SS-) may not lead to adverse effects related to neoplasm.
Rule 7: If a molecule contains a naphthyl group (-C10H7) or a phenyl group (-C6H5), it could potentially lead to adverse effects related to neoplasms.
Rule 8: The presence of a bromine atom in a molecule may indicate its potential for causing adverse effects related to neoplasms.
Rule 9: If a molecule contains a nitrogen atom bonded to a carbon atom through two single bonds indicating a primary amine, it may have the potential to cause adverse effects related to neoplasms.
Rule 10: A molecule containing a conjugated carbonyl group might lead to adverse effects related to neoplasms.
Rule 11: Substructures featuring the nitrogenous base cytosine might increase a molecule's potential to cause adverse effects related to neoplasms.
Rule 12: If a molecule has the substructure containing fluorinated organic compound hexafluoropropene, it may lead to adverse effects related to neoplasms.
Rule 13: The presence of certain functional groups like nitro or sulfonamide groups in a compound may increase its toxicity.
Rule 14: Large, complex molecular structures may have difficulty penetrating cell membranes which might lead to adverse effects whereas smaller molecules may be more likely to have toxic effects.
Rule 15: The chemical reactivity of a molecule can also determine its potential for causing adverse effects.
Rule 16: If a molecule contains a chloro group (-Cl) attached to a benzene ring, it may have the potential to cause adverse effects related to neoplasms.
Rule 17: A molecule containing a nitro group (-NO2) or a carbonyl group (-C=O) conjugated with an aromatic ring, has a potential to cause adverse effects related to neoplasms.
Rule 18: If a molecule contains the substructure: "C1=CC(=CC=C1C(=O)NCC(=O)O)N" or "CC1=C(C=CC2=C1C(=[NH+]C(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC", then it may have the potential to cause adverse effects related to neoplasms.
Rule 19: If a molecule contains the substructure "CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N" or "C(CCCC(=O)O)CCCC(=O)O", it may have the potential to cause adverse effects related to neoplasms.
Rule 20: If a molecule contains both a sulfonamide group (-SO2NH2) and a halogen atom such as chlorine (-Cl), it has a greater potential for causing adverse effects on neoplasms. 
Rule 21: The presence of nitro group (-NO2) or nitrate group (-ONO2) in a molecule could potentially lead to adverse effects related to neoplasms benign, malignant and unspecified.
Rule 22: If a molecule contains both a sulfonamide group (-SO2NH2) and chlorine atom (-Cl), it may have a greater potential for causing adverse effects on neoplasms.
Rule 1: Molecules containing the substructure CN1C2=C(C=C(C=C2)N(CCl)CCl)N=C1CCCC(=O)O have potential for neoplasm-related side-effects.
Rule 2: Molecules containing the substructure CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=C(C5=C4)CN(C)C)O)O have potential for neoplasm-related side-effects.
Rule 3: Molecules containing the substructure CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC have potential for neoplasm-related side-effects.
Rule 4: Molecules containing a sulfonamide group (-SO2NH-) or a benzene ring with a sulfonamide substituent (-SO2NH2) have potential for neoplasm-related side-effects.
Rule 5: Molecules with negatively charged oxygen atoms bonded to at least one carbon atom have potential for neoplasm-related side-effects.
Rule 6: Molecules that contain a nitro group (-NO2) or a halogen atom such as bromine (Br) attached to a benzene ring have potential for neoplasm-related side-effects.
Rule 7: Molecules containing a nitrogen-containing heterocyclic ring such as pyrazole or imidazole have potential for neoplasm-related side-effects.
Rule 8: If the molecule contains a nitro group (-NO2) attached to an aromatic ring, it may lead to neoplasm related adverse effects.
Rule 9: Molecules containing a coumarin moiety, represented by the SMARTS pattern "c1ccc2cc(oc1=O)cc2" may not cause neoplasm related side-effects.
Rule 10: Molecules containing both a nitro group (-NO2) attached to an aromatic ring and a coumarin moiety may or may not have potential for neoplasm-related side-effects, depending on other structural features of the molecule.
Rule 11: Molecules that contain a sulfonamide group (-SO2NH-) or a carbonyl group (-C=O) have potential for neoplasm-related side-effects.
Rule 12: Molecules with a fluorine atom bonded to a carbon atom in the indicated position (based on the SMILES string CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F) may relate to neoplasm benign, malignant and unspecified side-effects.
Rule 13: Molecules with a functional group represented by the SMILES string CCC(=O)NNC(=O)C(c2ccc(cc2)n2cnc3ccccc32)C(=O)Nc1ccc(cc1)nn1cnc2ccccc21 may have potential for neoplasm-related side-effects.
Rule 14: Molecules with a functional group represented by the SMILES string C#CC1=C(C(=O)NS(=O)(=O)C2=C(C=C(C=C2Br)Br)Br)SC(=O)N1C may have potential for neoplasm-related side-effects.
Rule 15: If the molecule contains a chlorine atom bonded to a carbon atom that is part of a ring structure containing at least one nitrogen atom, it may lead to neoplasm-related side effects.
Rule 16: If the molecule contains a fluorine atom attached to a carbon atom that is part of a ring structure containing at least two oxygen atoms, it may lead to neoplasm-related side effects.
Rule 17: If the molecule contains a carbonyl group (represented by the SMILES notation "C=O") followed by a single bond to another carbon atom, which is also connected to a nitrogen atom through a single bond, it may lead to neoplasm-related side-effects.
